Foundayo: Eli Lilly's Oral GLP-1 Pill for Weight Loss Now Available in the U.S. Eli Lilly has launched Foundayo, an innovative oral GLP-1 medication for weight loss, now accessible to adults battling obesity in the U.S.

Foundayo: Eli Lilly's Oral GLP-1 Pill for Weight Loss Now Available in the U.S. #USA #Indianapolis #Eli_Lilly #Orforglipron #Foundayo

Eli Lilly's Foundayo™ Now Available: A Revolutionary Pill for Weight Loss Eli Lilly announces the launch of Foundayo™, their revolutionary GLP-1 pill for weight loss, now accessible across the U.S. healthcare system.

Eli Lilly's Foundayo™ Now Available: A Revolutionary Pill for Weight Loss #United_States #Indianapolis #Eli_Lilly #Orforglipron #Foundayo™

FDA grants speedy approval to Eli Lilly's weight-loss pill for obesity The Food and Drug Administration's decision Wednesday means patients in the United States will soon have access to a second daily oral medication to treat obesity and weight-related issues.

FDA grants speedy approval to Eli Lilly's weight-loss pill for obesity

#orforglipron

www.pbs.org/newshour/hea...
PBS 4/1/2026

FDA approves Foundayo, an oral GLP-1, for adults with obesity The FDA approved a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight with weight-related comorbidities, Eli Lilly announced.

This week, the FDA approved Foundayo, Eli Lilly's #orforglipron, a once-daily oral GLP-1 receptor agonist

💊 Orforglipron can be taken without food or water restrictions

Read @gohealio.bsky.social's initial coverage here:
www.healio.com/news/endocri...

More to come!

Gespot op donderdag 2 april 2026

Eli Lilly’s afslankpil: revolutie binnen een revolutie
www.foodlog.nl/gespot/2026-...
#gezondheid #elililly #orforglipron #glp1 #afslankmiddelen #afslankpil

FDA Approves Foundayo™: A Flexible Weight Loss Pill to Simplify Daily Health Routines The FDA has authorized Foundayo™, a unique GLP-1 weight loss medication by Eli Lilly, allowing flexible daily use without food or water restrictions.

FDA Approves Foundayo™: A Flexible Weight Loss Pill to Simplify Daily Health Routines #USA #Indianapolis #Eli_Lilly #Orforglipron #Foundayo™

Comparative Efficacy of Wegovy® Over Orforglipron Revealed at Obesity Medicine Association 2026 A recent study indicates that Wegovy® pills are more effective for weight loss than orforglipron, with fewer side effects leading to medication discontinuation, as presented at a major medical conference.

Comparative Efficacy of Wegovy® Over Orforglipron Revealed at Obesity Medicine Association 2026 #USA #San_Diego #Novo_Nordisk #Wegovy #Orforglipron

Wegovy® Pill Shows Superior Weight Loss in Recent Study Compared to Orforglipron A new study reveals that the Wegovy® pill leads to greater weight loss than orforglipron, with fewer patients stopping due to side effects, enhancing obesity treatment options.

Wegovy® Pill Shows Superior Weight Loss in Recent Study Compared to Orforglipron #USA #San_Diego #Wegovy #Obesity_Treatment #Orforglipron

Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.

#EliLilly has claimed US approval for oral GLP-1 agonist #orforglipron (under the name #Foundayo) setting up a market clash with #NovoNordisk 's first-to-market #Wegovy pill.

Eli Lilly's Foundayo™ Receives FDA Approval for Flexible Weight Loss Treatment Eli Lilly's Foundayo™ (orforglipron) is a groundbreaking GLP-1 weight loss pill approved by the FDA, offering treatment flexibility for obesity.

Eli Lilly's Foundayo™ Receives FDA Approval for Flexible Weight Loss Treatment #United_States #Indianapolis #Eli_Lilly #Orforglipron #Foundayo

To by byla bomba. Účinější než semaglutid, mnohem pohodlnější a levnější. Jede třetí fáze licencování, uvedení na trh 26-27, pokud vše půjde dobře.

RE: libera.site/item/ed9a319d-93a2-52c1-...

#Orforglipron

Oral Orforglipron Noninferior, Superior to Oral Semaglutide for T2D Oral orforglipron demonstrated noninferiority and superiority to oral semaglutide for HbA1c reduction in adults with type 2 diabetes.

Both 12-mg and 36-mg doses of #orforglipron demonstrated superior glycemic control compared with 7-mg and 14-mg oral #semaglutide.

Read More: https://bit.ly/4lzSTNc

Orforglipron orale supera semaglutide in controllo glicemico e perdita di peso SESTO FIORENTINO (ITALPRESS) – Eli Lilly and Company ha annunciato oggi i risultati dettagliati di ACHIEVE-3, il primo studio di Fase 3 testa-a-testa che ha valutato sicurezza ed efficacia di orforglipron, una piccola molecola ...

TI POTREBBE INTERESSARE: Orforglipron orale supera semaglutide in controllo glicemico e perdita di peso ... LEGGI TUTTO #Orforglipron #Semaglutide #ControlloGlicemico #PerditaDiPeso #EliLilly

New GLP-1 Pill Orforglipron Outperforms Rybelsus in Trial Orforglipron, a new GLP-1 pill, outperforms Rybelsus in blood sugar control and weight loss in late-stage Type 2 diabetes trial.

New GLP-1 Pill Orforglipron Outperforms Rybelsus in Trial #Diabetes #GLP1 #Rybelsus #Orforglipron #Type2Diabetes

Orforglipron orale supera semaglutide in controllo glicemico e perdita di peso SESTO FIORENTINO (ITALPRESS) – Eli Lilly and Company ha annunciato oggi i risultati dettagliati di ACHIEVE-3, il primo studio di Fase 3 testa-a-testa che ha valutato sicurezza ed efficacia di orforglipron, una piccola molecola ...

È ACCADUTO IERI: Orforglipron orale supera semaglutide in controllo glicemico e perdita di peso ... LEGGI TUTTO #Orforglipron #Semaglutide #ControlloGlicemico #PerditaDiPeso #EliLilly

Lilly's Orforglipron Outshines Semaglutide in Diabetes Management: A Landmark Study Eli Lilly's recent Phase 3 trial reveals that orforglipron offers superior blood sugar control and weight loss in type 2 diabetes compared to semaglutide.

Lilly's Orforglipron Outshines Semaglutide in Diabetes Management: A Landmark Study #USA #Indianapolis #diabetes_management #Lilly #Orforglipron

Lilly says orforglipron tops Wegovy pill in diabetes trial Lilly's head-to-head trial of oral GLP-1 orforglipron and Novo Nordisk's oral Wegovy in type 2 diabetes raises as many questions as it answers.

#EliLilly's oral #GLP1 agonist #orforglipron was more effective than #NovoNordisk's recently launched #Wegovypill in a head-to-head #diabetestrial, but likely won't answer the question of which is better.

pharmaphorum.com/news/lilly-s...

Orforglipron offers greater weight loss for people with diabetes than oral semaglutide Novel weight-loss pill orforglipron (Emgality; Eli Lilly) offers patients with type 2 diabetes mellitus (T2DM) better blood sugar control and more weight loss than semaglutide — the only other GLP-1…

Patients with #type2diabetes taking weight-loss pill #orforglipron achieved better blood sugar control and more weight loss than those on #semaglutide in pill form, research shows

#weightloss #Emgality #EliLilly #diabetesmellitus #T2DM

buff.ly/vRMS2ir

Orforglipron orale supera semaglutide in controllo glicemico e perdita di peso SESTO FIORENTINO (ITALPRESS) – Eli Lilly and Company ha annunciato oggi i risultati dettagliati di ACHIEVE-3, il primo studio di Fase 3 testa-a-testa che ha valutato sicurezza ed efficacia di orforglipron, una piccola molecola ...

Orforglipron orale supera semaglutide in controllo glicemico e perdita di peso ... LEGGI TUTTO #Orforglipron #Semaglutide #ControlloGlicemico #PerditaDiPeso #EliLilly

The race between #WegovyTablets and #orforglipron might be like the story of the tortoise and the hare. But it's not clear which is which. The Wegovy tablet launch is exceeding expectations.
@novonordisk.bsky.social @elilillyandcompany.bsky.social
conscienhealth.org/2026/01/20/s...

Eli Lilly CFO Lucas Montarce told Bloomberg the company remains on track for a potential FDA approval of its obesity pill orforglipron in Q2 2026

#LLY #EliLilly #Orforglipron #GLP1 #ObesityDrug

Gespot op dinsdag 23 december 2025

De eerste afvalpil is een feit en werkt mogelijk beter dan een spuit www.foodlog.nl/gespot/2025-... #novonordisk #wegovy #afslankpil #elililly #orforglipron

Perhaps the most interesting story for 2026 got started late yesterday with FDA approval of #Wegovy tablets for #obesity. Will this headstart for @novonordisk.bsky.social sk give them a sustainable lead over @elilillyandcompany.bsky.social and #orforglipron?
conscienhealth.org/2025/12/a-we...

#Orforglipron #LLY

Health news round-up: orforglipron, new gonorrhoea antibiotics and record high flu admissions This week, The Pharmaceutical Journal has been reflecting on the past year, considering how the pharmacy sector has grown and presenting the headline numbers from our coverage across pharmacy in…

A weekly summary of important developments in health news that you may have missed: #orforglipron, new #gonorrhoea antibiotics and record high #flu admissions

#pharmacynews #newsinbrief #ukpharmacy

buff.ly/2f3PltV

Orforglipron Reduces Body Weight, A1C in Adults With Obesity and T2D Topline data were announced from a phase 3 trial evaluating orforglipron, an oral GLP-1 receptor agonist, in adults with obesity or overweight and T2D.

Improvements in #cardiometabolic risk factors were also seen in patients treated with #orforglipron.

Read More: https://bit.ly/3LtyKum

Lilly's Orforglipron Shows Promise for Sustaining Weight Loss in Obesity Treatment Eli Lilly's orforglipron demonstrates significant efficacy in maintaining weight loss after switching from injectable therapies in a groundbreaking trial.

Lilly's Orforglipron Shows Promise for Sustaining Weight Loss in Obesity Treatment #United_States #Indianapolis #Eli_Lilly #Obesity_Treatment #Orforglipron

Screenshot des im Post verlinkten Print-Artikels: Comiczeichnung eines alten Kaugummi-Automats als Logo der Kolumne "Wirkstoff des Monats". Daneben Überschrift „Orforglipron” und ersten Zeilen des Artikeltexts.

Den #WirkstoffdesMonats des Novemberhefts 11/2025 wollen wir trotz eingetretener Adventszeit nicht vorenthalten: #Orforglipron bindet wie andere #Abnehmmedikamente an den GLP-1 Rezeptor, kann aber als Tablette verabreicht werden … Mehr von Karin Hollricher unter www.laborjournal.de/rubric/wirks...

Daily #obesity pills are coming. Here are five things to know about them. Novo Nordisk's obesity pill is expected to win #FDA approval before the end of the year. Eli Lilly will submit #orforglipron for approval this year

¿Pastilla en vez de pinchazo? Orforglipron reta a Ozempic ya Orforglipron, la pastilla que compite con Ozempic: 72 semanas en diabetes y peso, toma diaria sin agujas y posible llegada en 2026, detalles. Orforglipron irrumpe como una opción oral, diaria y de mol...

¿Pastilla en vez de pinchazo? Orforglipron reta a Ozempic ya #orforglipron #Ozempic #GLP1 #diabetes #obesidad #perdidapeso #medicina #salud #TheLancet #EMA #farmacia #innovacion #23denoviembre #felizdomingo #España

donporque.com/orforglipron...